Alnylam Pharmaceuticals, Inc.
ALNY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178670
No open-market purchases or sales by Alnylam Pharmaceuticals, Inc. insiders were filed in the last 90 days; 794 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Alnylam Pharmaceuticals, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 424 | 4 | 497 | +77 |
| Shares | 113.5M | 30.4K | 133.4M | +19.9M (+17.5%) |
| Value | $16.6B | $4.49M | $26.7B | +$10.1B (+61.3%) |
4 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (117)
Institutions that held Alnylam Pharmaceuticals, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Showing the largest 100 of 117 by value.
Sold out (40)
Institutions that held Alnylam Pharmaceuticals, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
Not filed for Q3 2022 yet (4)
Institutions that held Alnylam Pharmaceuticals, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Taylor Wealth Management Partners | 24,190 | $3.53M |
| Brewin Dolphin Ltd | 5,000 | $729.0K |
| Quintet Private Bank (Europe) S.A. | 1,217 | $230.9K |
| Private Capital Group, LLC | 8 | $1.00K |